Developer docs
API playgroundTry for free, no card

Search company profiles

BioNxt Solutions

Full company profile

uuid0000ypq

Namestring
BioNxt Solutions
Legal namestring
BioNxt Solutions Inc.
Websiteurl
bionxt.com
Company typeenum
Public
Founded yearint
2018
Descriptiontext

BioNxt Solutions Inc. is a Vancouver, Canada-based, publicly traded (TSE:BNXT) clinical-stage biopharmaceutical company developing a proprietary sublingual oral dissolvable film (ODF) drug delivery platform for reformulating established therapeutics into swallow-free, needle-free dosage forms. The lead asset, BNT23001, is a patented sublingual cladribine ODF targeting multiple sclerosis and myasthenia gravis, with preclinical data showing approximately 40% higher blood exposure than conventional oral cladribine tablets. A second program applies the same platform to GLP-1 receptor agonists, starting with semaglutide for obesity, metabolic disorders, and type 2 diabetes, with plans to extend to tirzepatide and liraglutide.

The technology stack combines formulation know-how for ODF manufacture with a pending drug chaperone technology (under non-binding LOI) intended to enhance drug stability, absorption, and delivery consistency. Clinical-grade GMP production of the Cladribine ODF was completed in April 2026 at a Munich contract manufacturing partner to supply the planned first-in-human bioavailability study CBN26001. Semaglutide ODF development is conducted with German partner Gen-Plus GmbH. The intellectual property portfolio comprises granted European Patent No. 4539857 (effective March 11, 2026, valid through at least June 14, 2043 across up to 39 EPC states), an Eurasian patent across 8 member states, and a Track One priority filing at the USPTO.

BioNxt operates without commercialized products or product revenue. Its stated business model is partnership-driven: exclusive licensing agreements with pharmaceutical counterparties, co-development collaborations, and royalty-based supply arrangements, with a Business Development & Licensing specialist advisor engaged in June 2026 to commercialize BNT23001. The company is funded primarily through repeated non-brokered private placements, supplemented by a convertible debenture tranche in July 2025, with proceeds directed to European R&D, IP, and working capital. Headcount sits at 11–50 employees and the company is led by co-founder and CEO Hugh Rogers, co-founder and CFO Wolfgang Probst, and co-founder and director Raimar Löbenberg.

Short descriptiontext

BioNxt Solutions is a Vancouver-based, publicly traded clinical-stage biopharmaceutical company developing a proprietary sublingual oral dissolvable film drug delivery platform, with a lead cladribine ODF asset for multiple sclerosis and an early-stage semaglutide ODF program targeting the GLP-1 obesity market.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sublingual drug delivery, oral dissolvable films, pharmaceutical formulations, peptide therapeutics, biopharmaceutical development
Industry4 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Drug Delivery
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing Agreements
TypeLicensing Royalties
Description

The company plans to generate revenue through licensing its drug delivery technology and patented formulations to pharmaceutical partners, including upfront payments, milestone payments, and ongoing royalties.

pharmiweb.com
2Co-development Collaborations
TypeLicensing Royalties
Description

Revenue from joint development partnerships with pharmaceutical companies where BioNxt contributes its ODF platform technology in exchange for development funding and commercialization rights.

biospace.com
3Royalty-based Supply Arrangements
TypeLicensing Royalties
Description

Potential royalty-based supply arrangements with pharmaceutical partners for commercialized products using the sublingual drug delivery platform.

pharmiweb.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

BioNxt Solutions develops and commercializes proprietary sublingual oral dissolvable film (ODF) drug delivery formulations for peptide and small molecule therapeutics. Its lead product candidate BNT23001 is a swallow-free, needle-free sublingual cladribine ODF for multiple sclerosis, demonstrated to provide approximately 40% higher blood exposure than conventional oral tablets in preclinical studies. The company also advances a Semaglutide ODF program as the lead application of a broader GLP-1 ODF platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Approximately 40% higher blood exposure compared to conventional oral tablets in preclinical studies
+2 more records
Product overview1 text field

BioNxt Solutions is a bioscience company developing a proprietary sublingual oral dissolvable film (ODF) drug delivery platform. The company's core product is BNT23001, a patented sublingual Cladribine ODF for multiple sclerosis treatment. BioNxt is advancing a Semaglutide ODF program as the first application of its broader GLP-1 ODF Platform strategy, targeting obesity, metabolic disorders, and type 2 diabetes. The platform technology is being expanded to include tirzepatide and liraglutide formulations. The company has also secured drug chaperone technology to enhance its ODF platform and acquired rights to a sublingual formulation for oncology treatments. Development is conducted in Germany through partner Gen-Plus GmbH, with operations in North America and Europe.

Product and service3 records
1BNT23001 (Sublingual Cladribine Oral Dissolvable Film)
CategoryPharmaceutical Product Candidate
Description

Patented sublingual cladribine orally dissolvable film formulation intended as a swallow-free, needle-free alternative to conventional Mavenclad tablets for multiple sclerosis and myasthenia gravis treatment. Licensed to pharmaceutical partners for commercialization.

2Semaglutide Oral Dissolvable Film Program
CategoryPharmaceutical Product Candidate
Description

Oral thin-film formulation of semaglutide being developed for sublingual delivery of GLP-1 receptor agonist therapy, intended for pharmaceutical partners commercializing obesity and metabolic disorder treatments.

3Sublingual Oncology Formulation
CategoryPharmaceutical Product Candidate
Description

Novel sublingual drug formulation for oncology and immunosuppressant treatments being co-developed with a European-based chemotherapy company, expanding BioNxt's intellectual property portfolio and product pipeline.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-15
Description

Engaged advisor to support commercialization and partnering strategy for BNT23001, the patented sublingual Cladribine orally dissolvable film formulation for multiple sclerosis treatment.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-19
Description

German pharmaceutical development partner collaborating with BioNxt on the Semaglutide oral dissolvable film program. Gen-Plus provides active pharmaceutical development services for the GLP-1 ODF program targeting obesity, metabolic disorders, and type 2 diabetes.

3Contract Manufacturing Partner (Munich, Germany)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-14
Description

Contract manufacturing partner in Munich, Germany responsible for GMP production of clinical-grade sublingual Cladribine oral thin film for human bioavailability studies.

stocktitan.net
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-03-17
Description

Non-binding letter of intent establishing exclusive negotiation framework toward potential regional licensing agreement for sublingual cladribine oral thin film within Eurasian Patent Organization member states, with 60-day exclusivity period.

5Third-party Biotechnology Developer
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-05
Description

Non-binding letter of intent to secure exclusive rights to advanced drug chaperone technology for oral dissolvable thin-film applications to enhance drug stability, absorption efficiency, and delivery consistency.

biospace.com
6European-based Chemotherapy Company
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Letter agreement signed to acquire 100% interest in IP and co-develop a sublingual drug formulation for oncology and immunosuppressant treatments.

pharmiweb.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Oral thin film drug delivery company developing sublingual and buccal films for multiple therapeutic areas. Closely comparable as a smaller ODF-focused drug delivery specialist with a partnership-driven commercialization model.

TypeDirect peer
Description

Specialty pharma company commercializing sublingual and oral soluble film drug delivery products including Sympazan and Libervant. Directly comparable as a sublingual ODF platform company focused on reformulating approved molecules with proprietary thin-film technology.

TypeDirect peer
Description

Developer of oral thin-film and VersaFilm drug delivery platforms for pharmaceutical partners, with a comparable focus on reformulating small molecules via oral dissolvable/sublingual formats. Mirrors BioNxt's licensing-driven, small-cap specialty pharma model.

TypeDirect peer
Description

Specialty pharma and CDMO focused on oral thin film (Oralthin), orally disintegrating tablets, and taste-masked formulations. Operates as both an ODF technology licensor and contract manufacturer, comparable to BioNxt's sublingual ODF offering.

TypeDirect peer
Description

Established German developer and manufacturer of oral thin-film and transdermal drug delivery systems serving global pharma partners. Directly comparable as a European-based ODF platform licensor with GMP manufacturing capabilities similar to BioNxt's Munich partner arrangement.

TypeDirect peer
Description

Developer of oral thin-film dosage forms for pharmaceutical compounds including cannabinoids and therapeutics. Comparable as an ODF drug delivery platform company pursuing licensing and partnership revenues.

TypeRegional player
Description

European-based developer and manufacturer of transdermal and oral thin film drug delivery systems. Comparable as a European ODF specialist, though primarily serving EU regional customers rather than competing directly in BioNxt's core indications.

8Emisphere Technologies (Eligen technology)
TypeDirect peer
Description

Develops the Eligen carrier-based oral delivery technology for small molecules and peptides, focused on enabling oral administration of peptides and other poorly absorbed drugs. Comparable to BioNxt's GLP-1 ODF ambition of delivering injectable peptide therapeutics orally.

TypeBroad incumbent
Description

Global pharmaceutical company marketing Mavenclad (oral cladribine) for multiple sclerosis, generating approximately €1.2 billion in 2025 revenues. Relevant incumbent for BNT23001's competitive context in MS, though broader portfolio spans many therapy areas.

10Tapemark
TypeEmerging player
Description

Contract developer of oral dissolvable films and transdermal patches for pharmaceutical partners. Comparable as a smaller ODF/CDMO service provider in BioNxt's broader drug delivery ecosystem.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioNxt Solutions

Pharmaceutical Drug Deliverybionxt.com

BioNxt Solutions is a Vancouver-based, publicly traded clinical-stage biopharmaceutical company developing a proprietary sublingual oral dissolvable film drug delivery platform, with a lead cladribine ODF asset for multiple sclerosis and an early-stage semaglutide ODF program targeting the GLP-1 obesity market.

What BioNxt Solutions does

BioNxt Solutions Inc. is a Vancouver, Canada-based, publicly traded (TSE:BNXT) clinical-stage biopharmaceutical company developing a proprietary sublingual oral dissolvable film (ODF) drug delivery platform for reformulating established therapeutics into swallow-free, needle-free dosage forms. The lead asset, BNT23001, is a patented sublingual cladribine ODF targeting multiple sclerosis and myasthenia gravis, with preclinical data showing approximately 40% higher blood exposure than conventional oral cladribine tablets. A second program applies the same platform to GLP-1 receptor agonists, starting with semaglutide for obesity, metabolic disorders, and type 2 diabetes, with plans to extend to tirzepatide and liraglutide.

The technology stack combines formulation know-how for ODF manufacture with a pending drug chaperone technology (under non-binding LOI) intended to enhance drug stability, absorption, and delivery consistency. Clinical-grade GMP production of the Cladribine ODF was completed in April 2026 at a Munich contract manufacturing partner to supply the planned first-in-human bioavailability study CBN26001. Semaglutide ODF development is conducted with German partner Gen-Plus GmbH. The intellectual property portfolio comprises granted European Patent No. 4539857 (effective March 11, 2026, valid through at least June 14, 2043 across up to 39 EPC states), an Eurasian patent across 8 member states, and a Track One priority filing at the USPTO.

BioNxt operates without commercialized products or product revenue. Its stated business model is partnership-driven: exclusive licensing agreements with pharmaceutical counterparties, co-development collaborations, and royalty-based supply arrangements, with a Business Development & Licensing specialist advisor engaged in June 2026 to commercialize BNT23001. The company is funded primarily through repeated non-brokered private placements, supplemented by a convertible debenture tranche in July 2025, with proceeds directed to European R&D, IP, and working capital. Headcount sits at 11–50 employees and the company is led by co-founder and CEO Hugh Rogers, co-founder and CFO Wolfgang Probst, and co-founder and director Raimar Löbenberg.

BioNxt Solutions firmographics

Firmographics
Name
BioNxt Solutions
Legal name
BioNxt Solutions Inc.
Website
https://bionxt.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
BioNxt Solutions is a Vancouver-based, publicly traded clinical-stage biopharmaceutical company developing a proprietary sublingual oral dissolvable film drug delivery platform, with a lead cladribine ODF asset for multiple sclerosis and an early-stage semaglutide ODF program targeting the GLP-1 obesity market.
Ownership category
akta.pro rank

BioNxt Solutions industry classification

Industry
Product category
Pharmaceutical Drug Delivery
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing

Keywords

  • Sublingual drug delivery
  • Oral dissolvable films
  • Pharmaceutical formulations
  • Peptide therapeutics
  • Biopharmaceutical development

Where BioNxt Solutions is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

BioNxt Solutions business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

  1. Licensing Agreements: The company plans to generate revenue through licensing its drug delivery technology and patented formulations to pharmaceutical partners, including upfront payments, milestone payments, and ongoing royalties.
  2. Co-development Collaborations: Revenue from joint development partnerships with pharmaceutical companies where BioNxt contributes its ODF platform technology in exchange for development funding and commercialization rights.
  3. Royalty-based Supply Arrangements: Potential royalty-based supply arrangements with pharmaceutical partners for commercialized products using the sublingual drug delivery platform.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

BioNxt Solutions product offering

Product offering

Core offering

BioNxt Solutions develops and commercializes proprietary sublingual oral dissolvable film (ODF) drug delivery formulations for peptide and small molecule therapeutics. Its lead product candidate BNT23001 is a swallow-free, needle-free sublingual cladribine ODF for multiple sclerosis, demonstrated to provide approximately 40% higher blood exposure than conventional oral tablets in preclinical studies. The company also advances a Semaglutide ODF program as the lead application of a broader GLP-1 ODF platform.

Product overview

BioNxt Solutions is a bioscience company developing a proprietary sublingual oral dissolvable film (ODF) drug delivery platform. The company's core product is BNT23001, a patented sublingual Cladribine ODF for multiple sclerosis treatment. BioNxt is advancing a Semaglutide ODF program as the first application of its broader GLP-1 ODF Platform strategy, targeting obesity, metabolic disorders, and type 2 diabetes. The platform technology is being expanded to include tirzepatide and liraglutide formulations. The company has also secured drug chaperone technology to enhance its ODF platform and acquired rights to a sublingual formulation for oncology treatments. Development is conducted in Germany through partner Gen-Plus GmbH, with operations in North America and Europe.

Differentiator

Problem solved

Functional benefit

Products and services

  • BNT23001 (Sublingual Cladribine Oral Dissolvable Film) Patented sublingual cladribine orally dissolvable film formulation intended as a swallow-free, needle-free alternative to conventional Mavenclad tablets for multiple sclerosis and myasthenia gravis treatment. Licensed to pharmaceutical partners for commercialization.
  • Semaglutide Oral Dissolvable Film Program Oral thin-film formulation of semaglutide being developed for sublingual delivery of GLP-1 receptor agonist therapy, intended for pharmaceutical partners commercializing obesity and metabolic disorder treatments.
  • Sublingual Oncology Formulation Novel sublingual drug formulation for oncology and immunosuppressant treatments being co-developed with a European-based chemotherapy company, expanding BioNxt's intellectual property portfolio and product pipeline.

Quantifiable outcome

  • Approximately 40% higher blood exposure compared to conventional oral tablets in preclinical studies
  • +2 more outcomes

Companies that use BioNxt Solutions

Customer profile

Segments3 records

Ideal customer profiles3 records

BioNxt Solutions technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

BioNxt Solutions partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and major.

  • Business Development & Licensing Specialist AdvisorcoreStrategic or Co-development Partner · 15 June 2026Engaged advisor to support commercialization and partnering strategy for BNT23001, the patented sublingual Cladribine orally dissolvable film formulation for multiple sclerosis treatment.
  • Gen-Plus GmbHcoreTechnology or Integration · 19 May 2026German pharmaceutical development partner collaborating with BioNxt on the Semaglutide oral dissolvable film program. Gen-Plus provides active pharmaceutical development services for the GLP-1 ODF program targeting obesity, metabolic disorders, and type 2 diabetes.
  • Contract Manufacturing Partner (Munich, Germany)coreStrategic or Co-development Partner · 14 April 2026Contract manufacturing partner in Munich, Germany responsible for GMP production of clinical-grade sublingual Cladribine oral thin film for human bioavailability studies.
  • Eurasian Patent Organization LicenseemajorOEM/ Whitelabel/ Licensing Partner · 17 March 2026Non-binding letter of intent establishing exclusive negotiation framework toward potential regional licensing agreement for sublingual cladribine oral thin film within Eurasian Patent Organization member states, with 60-day exclusivity period.
  • Third-party Biotechnology DevelopercoreTechnology or Integration · 5 February 2026Non-binding letter of intent to secure exclusive rights to advanced drug chaperone technology for oral dissolvable thin-film applications to enhance drug stability, absorption efficiency, and delivery consistency.
  • European-based Chemotherapy CompanycoreStrategic or Co-development Partner · 1 December 2025Letter agreement signed to acquire 100% interest in IP and co-develop a sublingual drug formulation for oncology and immunosuppressant treatments.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

BioNxt Solutions competitors and assessment

Company assessment

Direct peers

  • ARx LLC: Oral thin film drug delivery company developing sublingual and buccal films for multiple therapeutic areas. Closely comparable as a smaller ODF-focused drug delivery specialist with a partnership-driven commercialization model.
  • Aquestive Therapeutics: Specialty pharma company commercializing sublingual and oral soluble film drug delivery products including Sympazan and Libervant. Directly comparable as a sublingual ODF platform company focused on reformulating approved molecules with proprietary thin-film technology.
  • IntelGenx Technologies: Developer of oral thin-film and VersaFilm drug delivery platforms for pharmaceutical partners, with a comparable focus on reformulating small molecules via oral dissolvable/sublingual formats. Mirrors BioNxt's licensing-driven, small-cap specialty pharma model.
  • ZIM Laboratories: Specialty pharma and CDMO focused on oral thin film (Oralthin), orally disintegrating tablets, and taste-masked formulations. Operates as both an ODF technology licensor and contract manufacturer, comparable to BioNxt's sublingual ODF offering.
  • LTS Lohmann Therapie-Systeme: Established German developer and manufacturer of oral thin-film and transdermal drug delivery systems serving global pharma partners. Directly comparable as a European-based ODF platform licensor with GMP manufacturing capabilities similar to BioNxt's Munich partner arrangement.
  • Cure Pharmaceutical (The CURE Group): Developer of oral thin-film dosage forms for pharmaceutical compounds including cannabinoids and therapeutics. Comparable as an ODF drug delivery platform company pursuing licensing and partnership revenues.
  • Emisphere Technologies (Eligen technology): Develops the Eligen carrier-based oral delivery technology for small molecules and peptides, focused on enabling oral administration of peptides and other poorly absorbed drugs. Comparable to BioNxt's GLP-1 ODF ambition of delivering injectable peptide therapeutics orally.

Regional players

  • Adhex Pharma: European-based developer and manufacturer of transdermal and oral thin film drug delivery systems. Comparable as a European ODF specialist, though primarily serving EU regional customers rather than competing directly in BioNxt's core indications.

Broad incumbents

  • Merck KGaA (Mavenclad franchise): Global pharmaceutical company marketing Mavenclad (oral cladribine) for multiple sclerosis, generating approximately €1.2 billion in 2025 revenues. Relevant incumbent for BNT23001's competitive context in MS, though broader portfolio spans many therapy areas.

Emerging players

  • Tapemark: Contract developer of oral dissolvable films and transdermal patches for pharmaceutical partners. Comparable as a smaller ODF/CDMO service provider in BioNxt's broader drug delivery ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

BioNxt Solutions social profiles

Digital presence

BioNxt Solutions financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioNxt Solutions leadership team

Management profile

Number of profiles

Profiles3 records

BioNxt Solutions subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

BioNxt Solutions funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioNxt Solutions M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioNxt Solutions

What does BioNxt Solutions do?

BioNxt Solutions develops and commercializes proprietary sublingual oral dissolvable film (ODF) drug delivery formulations for peptide and small molecule therapeutics. Its lead product candidate BNT23001 is a swallow-free, needle-free sublingual cladribine ODF for multiple sclerosis, demonstrated to provide approximately 40% higher blood exposure than conventional oral tablets in preclinical studies. The company also advances a Semaglutide ODF program as the lead application of a broader GLP-1 ODF platform.

Is BioNxt Solutions a public or private company?

BioNxt Solutions is a public company. It is classified as public and is currently operating.

When was BioNxt Solutions founded?

BioNxt Solutions was founded in 2018. It employs 1 to 10 people.

Where is BioNxt Solutions based?

BioNxt Solutions is headquartered in Vancouver, Canada, in the North America region.

How does BioNxt Solutions make money?

Three revenue lines are on record. Licensing Agreements are the primary driver. The others are co-development Collaborations and royalty-based Supply Arrangements.

Who are BioNxt Solutions's main competitors?

Direct peers on record are ARx LLC, Aquestive Therapeutics, IntelGenx Technologies, ZIM Laboratories, LTS Lohmann Therapie-Systeme, Cure Pharmaceutical (The CURE Group) and Emisphere Technologies (Eligen technology). Adhex Pharma is listed as a regional player. Merck KGaA (Mavenclad franchise) is listed as a broad incumbent. Tapemark is listed as an emerging player.

Does BioNxt Solutions have an API?

No public API is recorded for BioNxt Solutions.

What industry is BioNxt Solutions in?

BioNxt Solutions's product category is Pharmaceutical Drug Delivery. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewBioNxt Solutions launches $2.5M private placement to fund R&DBioNxt Solutions announced a non-brokered private placement of up to 10 million units at $0.25 each, targeting gross proceeds of up to $2.5 million. Each unit includes a common share and a warrant to buy another share at $0.50 for 24 months. Net proceeds will fund European R&D, including a planned human clinical study, and working capital.Seeking AlphaBioNxt Solutions launches $2.5M private placement to fund R&DBioNxt Solutions announced a non-brokered private placement of up to 10 million units at $0.25 each, targeting gross proceeds of up to $2.5 million. Each unit includes one common share and one warrant to buy a share at $0.50 for 24 months. Net proceeds will fund European R&D, including a planned human clinical study, and working capital.Stock TitanBioNxt Solutions plans up to $2.5M private placementBioNxt Solutions announced a non-brokered private placement of up to 10 million units at $0.25 each, raising up to $2.5 million. Proceeds will fund European R&D, including a planned human clinical study, and working capital. The offering may close in tranches subject to CSE acceptance.TradingViewBioNxt Solutions Inc. (BNXT) Plans Private Placement of Up to $2.5MBioNxt Solutions Inc. announced a non-brokered private placement of up to 10 million units at $0.25 each, for gross proceeds of up to $2.5 million. Proceeds are intended for European R&D, including a planned human clinical study, and working capital. Closing is subject to CSE acceptance.TradingViewBioNxt Solutions Inc. Announces Non-Brokered Private Placement of UnitsBioNxt Solutions Inc. announced a non-brokered private placement of up to 10,000,000 units at $0.25 each, raising up to $2,500,000. Proceeds will fund European R&D, including a planned human clinical study, and working capital. The offering may close in tranches and is subject to CSE acceptance.FinanzNachrichten.deBioNxt Solutions Inc. Announces Non-Brokered Private Placement of UnitsBioNxt Solutions Inc. announced a non-brokered private placement of up to 10 million units at $0.25 each, raising up to $2.5 million. Proceeds will fund European R&D, including a planned human clinical study, and working capital. The offering may close in tranches and is subject to CSE acceptance.FinanzNachrichten.deSpannendes Pharma-Duell: Wer startet jetzt durch - BioNxt Solutions, Bayer oder Novo Nordisk?BioNxt Solutions, Bayer, and Novo Nordisk are compared in a pharmaceutical investment analysis. BioNxt focuses on new drug films, while Bayer and Novo Nordisk reported strong quarterly results, with Novo Nordisk demonstrating the commercial potential of innovative application forms in obesity therapy.FinanzNachrichten.dePharmaaktien mit Zukunft - Bayer, BioNxt Solutions, Novo Nordisk füllen ihre PipelinesBayer plans to invest $2.2 billion in a pharmaceutical plant in Ohio, while smaller developer BioNxt Solutions is working on new formulations of known drugs. Novo Nordisk agreed to a $300 million upfront payment for an oral drug license. These investments aim to offset patent expirations and rising competition.TradingViewBioNxt Solutions Inc. (BNXT) Files EU CTA, Completes GMP Batch for Cladribine ODFBioNxt Solutions submitted a Clinical Trial Application in the EU and completed GMP manufacturing of approximately 1,500 sublingual cladribine films for a planned bioequivalence study versus Mavenclad. The batch release is pending QC tests, with CTA review expected to take about three months.Defense WorldBioNxt Solutions Inc. (OTCMKTS:BNXTF) Sees Large Increase in Short InterestBioNxt Solutions saw short interest surge 500% to 6,000 shares as of September 30th, with a days-to-cover ratio of 13.0. The stock opened at $0.26, trading up 23.1% from its 52-week low of $0.14, and the company reported a quarterly loss of $0.01 per share.